GeneFerm Biotechnology Co Ltd (1796) — Financial Flexibility Index
GeneFerm Biotechnology Co Ltd (1796) has a Financial Flexibility Index of 0.02x as of June 2025. Free cash flow of NT$7.43 Million (operating CF NT$1.45 Million minus capex NT$5.98 Million) represents 0% of total liabilities (NT$453.10 Million). Also explore how fast is GeneFerm Biotechnology Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneFerm Biotechnology Co Ltd Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for GeneFerm Biotechnology Co Ltd across 8 annual periods. Check 1796 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year free cash flow to debt coverage for GeneFerm Biotechnology Co Ltd. For the full company profile including market capitalisation, see 1796 market cap.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.09x | NT$30.79 Million | NT$8.09 Million | NT$358.31 Million | ▼ -90.7% |
| 2023 | 0.93x | NT$261.72 Million | NT$190.31 Million | NT$282.54 Million | ▼ -17.1% |
| 2022 | 1.12x | NT$400.85 Million | NT$122.43 Million | NT$358.86 Million | ▲ +146.6% |
| 2021 | 0.45x | NT$257.84 Million | NT$112.23 Million | NT$569.22 Million | ▲ +91.4% |
| 2020 | 0.24x | NT$138.74 Million | NT$56.42 Million | NT$586.38 Million | ▼ -84.3% |
| 2019 | 1.51x | NT$69.26 Million | NT$14.69 Million | NT$46.00 Million | ▲ +198.6% |
| 2018 | 0.50x | NT$70.94 Million | NT$42.14 Million | NT$140.69 Million | ▼ -15.9% |
| 2017 | 0.60x | NT$116.23 Million | NT$61.08 Million | NT$193.79 Million | — |